Monthly Archives: April 2017

P30 Researcher Bruce Gelb Named President-Elect of the American Pediatric Society

P30 Center Member, Bruce D. Gelb, MD, has been elected President of the American Pediatric Society (APS) by the organization’s members. Dr. Gelb will serve as President-Elect from May 2017, and as President starting in May 2018.


Dr. Gelb is the Gogel Family Professor of Child Health and Development and Professor of Pediatrics, and Genetics and Genomic Sciences, at the Icahn School of Medicine at Mount Sinai, and Director of The Mindich Child Health and Development Institute.  He is an internationally acclaimed translational pediatric investigator and expert in Noonan syndrome. He has developed an extensive program in genomics, focusing on traits associated with heart malformations and the causes of congenital heart disease.


“I am honored to have been selected to lead the APS,” said Dr. Gelb. “Given the opportunities and challenges facing us today as we strive to improve the health and well-being of our nation’s children, the importance of the APS’s mission has never been clearer.”


The mission of the American Pediatric Society is to advance academic pediatrics.  The APS’s first president was Abraham Jacobi, who established the first pediatrics department in the United States at The Mount Sinai Hospital.

Dr. Horowitz interviewed by Genome Web About Patient Diversity in Cancer Research

On April 17, 2017, COEC Co-Director Dr. Carol Horowitz was interviewed by Genome Web about patient diversity in cancer research following her attendance at the annual meeting of the American Association for Cancer Research in Washington, DC. In the “Patient Diversity in Cancer Research Essential to Addressing Health Disparities, Scientists Say” article, Dr. Horowitz emphasizes the importance of addressing the lack of diversity in many large genomic datasets. Dr. Horowitz suggests that one way to ameliorate the problem is for researchers to come out of their silos. Researchers must recognize the problems faced by their target patient populations, and must work with as many stakeholders as possible to not only recruit a diverse set of people into studies, but to also clearly communicate how these studies could possibly help the participants themselves, or help their communities. To read the full article from Genome Web click here.